Riociguat: Clinical research and evolving role in therapy

Riociguat is a first‐in‐class soluble guanylate cyclase stimulator, approved for the treatment of adults with pulmonary arterial hypertension (PAH), inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after pulmonary endarterectomy. Approval was based o...

Descripción completa

Detalles Bibliográficos
Autores principales: Klinger, James R., Chakinala, Murali M., Langleben, David, Rosenkranz, Stephan, Sitbon, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359233/
https://www.ncbi.nlm.nih.gov/pubmed/33242341
http://dx.doi.org/10.1111/bcp.14676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359233/
https://www.ncbi.nlm.nih.gov/pubmed/33242341
http://dx.doi.org/10.1111/bcp.14676

Ejemplares similares